Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0F3WG
|
|||
| Former ID |
DIB009329
|
|||
| Drug Name |
Disufenton sodium
|
|||
| Synonyms |
Cerovive; ARL-16556; CPI-22; CXY-059; HPN-07; NXY-059; NXY-059G; OKN-007; S-PBN; Nitrones (cancer), Oklahoma Medical Research Foundation; Nitrones, Renovis/AstraZeneca; PBN derivatives, Renovis/AstraZeneca; Spin trap agents, Renovis/AstraZeneca
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Ischemia [ICD-11: 8B10-8B11; ICD-9: 459.89] | Phase 3 | [1] | |
| Recurrent glioblastoma [ICD-11: 2A00.00; ICD-10: C71] | Phase 1 | [2], [3] | ||
| Company |
AstraZeneca
|
|||
| Structure |
 |
Download2D MOL
|
||
| Formula |
C11H13NNa2O7S2
|
|||
| Canonical SMILES |
CC(C)(C)[N+](=CC1=C(C=C(C=C1)S(=O)(=O)[O-])S(=O)(=O)[O-])[O-].[Na+].[Na+]
|
|||
| InChI |
1S/C11H15NO7S2.2Na/c1-11(2,3)12(13)7-8-4-5-9(20(14,15)16)6-10(8)21(17,18)19;;/h4-7H,1-3H3,(H,14,15,16)(H,17,18,19);;/q;2*+1/p-2/b12-7-;;
|
|||
| InChIKey |
XLZOVRYBVCMCGL-BPNVQINPSA-L
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Free radical (FRD) | Target Info | Modulator | [4] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00061022) Safety and Effectiveness of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | NXY-059, a free radical--trapping agent, substantially lessens the functional disability resulting from cerebral ischemia in a primate species. Stroke. 2001 Jan;32(1):190-8. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.